Aarti Drugs Limited (AARTIDRUGS.NS)

502.60 +1.80 (+0.36%) At close: 03:29PM IST

Aarti Drugs Limited

Mahendra Industrial Estate
Ground Floor Road No. 29, Plot No. 109-D Sion (East)
Mumbai 400 022
India
91 22 2401 9025
https://www.aartidrugs.co.in

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,003

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Prakash Moreshwar Patil	Chairman, MD, CEO & Head of BR	27.65M	N/A	1947
Mr. Harshit Manila Savla	Joint MD & Executive Director	25.55M	N/A	1962
Mr. Adhish Prakash Patil	CFO & COO	N/A	N/A	1983
Mr. Rushikesh Vivek Deole	Company Secretary & Compliance Officer	N/A	N/A	N/A
Mr. Harit Pragji Shah	Whole-Time Director	25.55M	N/A	1963
Mr. Uday Moreshwar Patil	Whole-Time Director	3.19M	N/A	1963
Mr. Rashesh Chandrakant Gogri	MD & Executive Director	25.55M	N/A	1974
Mr. Dhanaji L. Kakade	Vice President of Technical	N/A	N/A	N/A
Mr. Vishwa Harshit Savla	Director of Pinnacle of Life Sciences	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

Aarti Drugs Limited, through its subsidiaries, engages in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company provides APls in various therapeutic areas, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, para toluene sulphonic acid methyl ester, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, sodium para toluene sulfinate, para toluene sulphonyl hydrazide, di-phenyl sulphone, formamide, ammonium sulfate, and calcium fluoride, as well as benzene sulphonic acid sodium salt, benzyl nicotinate, methyl nicotinate, ethyl para toluene sulphonate, N-methyl methane sulfonamide, benzene sulphonamide, 2-phenoxy methane sulphanilide, para toluene sulfonamides, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, and N-methyl methane sulfonamides. In addition, the company's development products portfolio comprises Itraconazole and Fluconazole for antifungal applications; Dabigatran for use as an anticoagulant; Ticagrelor for cardiovascular diseases; Sitagliptin for use as an antidiabetics; and Alpha Lipoic Acid for application as an antioxidants. Further, it provides contract manufacturing services; and develops dermatology products to address various dermatological conditions, which include dermatitis, psoriasis, acne, and eczema. Aarti Drugs Limited was incorporated in 1984 and is headquartered in Mumbai, India.

Corporate governance

Aarti Drugs Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.